Obermatt
See Similar Stocks →

Cumberland Pharmaceuticals

NSQ:CPIX · US2307701092
PharmaceuticalsSmall

360

28
Medium confidence — indicative
Profit price92
Owner Earnings Yield1
Dividend Yield1
Price/Sales84
EV / Gross Profit46
Price/Book31
Return on Capital26
Cash Return on Capital25
Return on Equity31
EBIT Margin16
Gross Profitability93
Accruals74
Owner Earnings Margin32
Sales growth11
Profit Growth58
Owner Earnings Growth15
Reinvestment28
Price momentum43
Debt load39
Refinancing8
Debt Payback1
Liquidity25
Analyst ratings—
Expectations trend—
Market mood9
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Cumberland Pharmaceuticals doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded1999
Employees92
Websitecumberlandpharma.com
ISINUS2307701092
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Pain ManagementCardiovascularInfectious DiseasesInternal DiseasesGastroenterologyPulmonologyRespiratoryOncologyBiotechnologyHealth Care

Description

Cumberland Pharmaceuticals Inc. (Cumberland) is a specialty pharmaceutical company. The company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. The company's primary target markets a…

Analysis

Middle-of-the-road

Cumberland Pharmaceuticals Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 2/20 on our value-creation score: not creating value.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
1
2026

All-time high

14

Mar 2026

All-time low

1

Jun 2026

Average rank

8

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
84
—
—
—
Price/Earnings
5
—
—
—
Price/Book
31
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
19
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Cumberland Pharmaceuticals with its peers
Supernus Pharma
NMQ:SUPN
81
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Innoviva
NSQ:INVA
95
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Merck (USA)
NYQ:MRK
35
CountryUSA
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Collegium Pharmaceutical
NSQ:COLL
100
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Corcept Therapeutics
NAQ:CORT
20
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
MIRA Pharmaceuticals
NAQ:MIRA
—
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →